Intel stock spikes after report of possible US government stake
Regenxbio Inc (NASDAQ:RGNX) stock has hit a 52-week low, dropping to $5.6, as the biotechnology company faces a challenging market environment. With a market capitalization of $291 million, InvestingPro analysis suggests the stock is currently undervalued, while analyst price targets range from $14 to $52. This latest price level reflects a significant downturn over the past year, with the stock experiencing a precipitous 1-year change of -69.2%. Despite the decline, InvestingPro data shows the company maintains a healthy balance sheet with more cash than debt and a strong current ratio of 2.69. Investors are closely monitoring the company's performance and potential catalysts that could influence its recovery or further descent in the market, with the next earnings report due in 23 days. The 52-week low serves as a critical point of observation for both shareholders and analysts who are assessing the stock's volatility and future prospects. For deeper insights, access the comprehensive Pro Research Report, available exclusively on InvestingPro, along with 7 additional key ProTips for RGNX.
In other recent news, Regenxbio Inc. reported its fourth-quarter revenue at $21.2 million, with a net loss of $51.2 million, outperforming analysts' expectations of a $65.9 million loss. For the full year of 2024, the company's revenue reached $83.3 million, with a net loss of $227.1 million. Regenxbio has also completed its Biologics License Application for RGX-121, a gene therapy for Mucopolysaccharidosis II, potentially positioning it for FDA approval by the second half of 2025. Analyst Yi Chen from H.C. Wainwright maintained a Buy rating but adjusted the price target to $34.00 from $36.00, reflecting the company's financial performance and BLA progress.
Clear Street initiated coverage of Regenxbio with a Buy rating and a $50.00 price target, highlighting the company's transition towards commercialization and its promising pipeline. Baird reaffirmed an Outperform rating with a $39.00 target, citing positive interim data from the AFFINITY DUCHENNE trial and a strong safety profile for RGX-202. Raymond (NSE:RYMD) James increased its price target to $29.00, maintaining an Outperform rating, following Regenxbio's presentation of updated trial results at a recent conference. These developments underscore Regenxbio's ongoing efforts in advancing gene therapies and its strategic positioning within the biotechnology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.